GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Sale Of Investment

Alliance Pharma (LSE:APH) Sale Of Investment : £0.0 Mil (TTM As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Sale Of Investment?

Alliance Pharma's sale of investment for the six months ended in Jun. 2023 was £0.0 Mil. It means Alliance Pharma gained £0.0 Mil from selling investments. Alliance Pharma's sale of investment for the trailing twelve months (TTM) ended in Jun. 2023 was £0.0 Mil.

Compared with last quarter (£0.0 Mil in Dec. 2022 ), Alliance Pharma gained the same money from selling investments in Jun. 2023 (£0.0 Mil).

Alliance Pharma Sale Of Investment Historical Data

The historical data trend for Alliance Pharma's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Sale Of Investment Chart

Alliance Pharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alliance Pharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alliance Pharma Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alliance Pharma Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Alliance Pharma (LSE:APH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Sale Of Investment
Comparable Companies
LSE:AGY LSE:ANCR LSE:EAH LSE:CEL LSE:VLG LSE:BMK LSE:PXS LSE:STX LSE:CHLL AQSE:ANA ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
DVL:Germany
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Website
https://www.alliancepharmaceuticals.com
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).